1. Home
  2. WAT vs RMD Comparison

WAT vs RMD Comparison

Compare WAT & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Waters Corporation

WAT

Waters Corporation

HOLD

Current Price

$303.90

Market Cap

29.3B

Sector

Industrials

ML Signal

HOLD

Logo ResMed Inc.

RMD

ResMed Inc.

HOLD

Current Price

$226.89

Market Cap

33.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WAT
RMD
Founded
1958
1989
Country
United States
United States
Employees
N/A
10600
Industry
Biotechnology: Laboratory Analytical Instruments
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.3B
33.2B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
WAT
RMD
Price
$303.90
$226.89
Analyst Decision
Buy
Buy
Analyst Count
17
10
Target Price
$386.38
$293.70
AVG Volume (30 Days)
999.3K
848.9K
Earning Date
05-05-2026
04-22-2026
Dividend Yield
N/A
1.05%
EPS Growth
0.47
N/A
EPS
10.76
N/A
Revenue
$3,165,286,000.00
N/A
Revenue This Year
$104.66
$10.58
Revenue Next Year
$10.53
$7.38
P/E Ratio
$28.06
$25.61
Revenue Growth
6.99
N/A
52 Week Low
$275.05
$199.92
52 Week High
$414.15
$293.81

Technical Indicators

Market Signals
Indicator
WAT
RMD
Relative Strength Index (RSI) 41.83 30.41
Support Level $281.62 N/A
Resistance Level $308.14 $260.21
Average True Range (ATR) 8.63 5.28
MACD 2.99 -1.26
Stochastic Oscillator 63.96 21.07

Price Performance

Historical Comparison
WAT
RMD

About WAT Waters Corporation

Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.

About RMD ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Share on Social Networks: